uniQure N.V. (NASDAQ:QURE) is a Hot Growth Stock to Invest in Now. H.C. Wainwright raised the price target on QURE from $70 to $110 with a Buy rating. The promising results from the AMT-130 trials have caused the stock to surge over 339%.

uniQure N.V. (NASDAQ:QURE) specializes in gene therapy, developing one-time gene therapies to potentially cure genetic and serious diseases. The 3-year data from the AMT-130 trials for Huntington’s disease show significant disease progression slowdown and biomarker improvements.

While QURE is a strong investment, some AI stocks may offer greater upside potential with less downside risk. A report on the best short-term AI stock is available for those seeking undervalued options.

Read more at Yahoo Finance: H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating